Table 3.

Risk of prostate cancer associated with NSAID daily dose among current long-term users (duration longer than 1 year)

Cases (n = 2183)
Controls (n = 10,000)
OR (95% CI)a
n (%)n (%)
Aspirin
    No use1675 (76.7)7675 (76.8)
    75 mg163 (7.5)751 (7.5)0.70 (0.58–0.85)
    150 mg94 (4.3)379 (3.8)0.82 (0.64–1.05)
    300 mg53 (2.4)255 (2.6)0.71 (0.52–0.98)
NA-NSAIDs
    No use879 (40.3)4582 (45.8)
    Low-mediumb92 (4.2)397 (4.0)0.88 (0.68–1.13)
    High77 (3.5)343 (3.4)0.90 (0.68–1.18)
Paracetamol
    No use972 (44.5)5009 (50.1)
    Low-mediumc180 (8.3)909 (9.1)0.66 (0.54–0.80)
    High25 (1.2)133 (1.3)0.59 (0.38–0.93)
  • a Estimates of risk are adjusted for age, calendar year, BPH prior history, number of visits to general practitioners, referrals, hospitalizations, and all the variables included in the table using logistic regression.

  • b Specific cutoff values for dose (in mg) by NA-NSAID were as follows: aceclofenac 100, acemetacin 120, apazone 600, diclofenac 100, etodolac 400, fenbufen 900, fenoprofen 1200, flurbiprofen 150, ibuprofen 1200, indomethacin 75, ketoprofen 150, mefenamic 1000, meloxicam 7.5, nabumetone 1000, naproxen 750, piroxicam 10, sulindac 200, tenoxicam 10, and tiaprofenic acid 450.

  • c Low-medium ≤2000 mg/day, high >2000 mg/day.